GOSS Stock Catalyst: Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights for Seralutinib

Jul 27, 2026 · 7:00am ET

Company provides a business update alongside the announcement.

Max move

+120.2%

High of day $0.30

Sparker timei

7:00am ET

GOSS · Jul 27, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Gossamer Bio, Inc. (Nasdaq: GOSS) announced an FDA regulatory update and the reacquisition of worldwide rights related to its drug candidate, seralutinib. The company also provided a business update detailing its current strategic direction and operational focus.

The reacquisition of worldwide rights for seralutinib marks a significant shift in Gossamer Bio's asset management strategy. The company did not disclose specific financial terms or timelines associated with this transition. Gossamer Bio's free float stands at 137,910,000 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time GOSS sparks.

Download Sniper App →

Catch the next GOSS-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →